RxDoctor Payments Data

Ronald Kimmel, MD

Internal Medicine · East Hartford, CTNPI 1649257338

Payments from drug & device makers

$21,610in general payments, 2019–2025

Across 1,072 payments — averaging $20.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$2K
  • AbbVie$2K
  • Abbott$2K
  • Boehringer Ingelheim$2K
  • GSK$2K
  • AstraZeneca$1K
  • plus $11K from 54 others

What the payments were for

  • Food & beverage$21,592100%
  • Education$170%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Lilly USA, LLC115$2,289
AbbVie(2 entities)103$1,958
Abbott89$1,840
Boehringer Ingelheim73$1,592
GSK76$1,516
AstraZeneca(2 entities)68$1,219
Amgen55$1,127
Sanofi-aventis U.S. LLC44$804
Pfizer35$703
Novo Nordisk33$651
Astellas Pharma US Inc24$556
Exact Sciences17$420
Mallinckrodt Hospital Products Inc.20$418
Corcept Therapeutics19$405
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC19$397
Lifescan, Inc.24$362
Johnson & Johnson17$280
Novartis15$265
Endo Pharmaceuticals Inc.15$252
Amneal Pharmaceuticals LLC12$249
Otsuka America Pharmaceutical, Inc.12$241
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)7$187
Bayer8$186
Dexcom, Inc.8$178
Xeris Pharmaceuticals, Inc.9$177
Actelion Pharmaceuticals US, Inc.6$176
Neurocrine Biosciences, Inc.6$161
Amryt Pharma Holdings Ltd8$156
Takeda Pharmaceuticals U.S.A., Inc.7$154
Cequr Corporation3$150
Amarin Pharma, Inc.7$148
Harmony Biosciences LLC7$139
Radius Health, Inc.5$118
Teleflex LLC2$113
Medtronic5$93
Insulet Corporation5$92
Almatica Pharma LLC4$89
Regeneron Healthcare Solutions, Inc.4$86
Chiesi USA, Inc.4$82
Mylan Specialty L.p.4$81
Sunovion Pharmaceuticals Inc.5$80
Ultragenyx Pharmaceutical Inc.4$76
Lundbeck LLC4$75
Verona Pharma, Inc.3$63
BD3$54
E.r. Squibb & Sons, L.L.C.2$49
Eisai Inc.3$48
Shield Therapeutics Inc2$46
Mannkind Corporation1$44
Acerus Pharmaceuticals Corporation3$42
Shire North American Group Inc2$41
Axsome Therapeutics, Inc.2$40
Indivior Inc.1$39
Alvogen Inc2$38
Inspire Medical Systems, Inc.1$38
Antares Pharma, Inc.2$37
Seqirus USA Inc2$36
Nabriva Therapeutics, PLC3$35
Recordati_rare_diseases_inc.2$34
Lexicon Pharmaceuticals, Inc.2$34

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,610 in reported general payments places this provider in the 95th percentile of 2,067 internal medicine providers in Connecticut.

See all internal medicine providers in Connecticut

Medicare billing

Part B allowed, 2024
$78,724
Medicare patients
177
Services billed
833

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide75$91,900
JardianceEmpagliflozin87$89,847
EliquisApixaban77$77,651
TrulicityDulaglutide63$71,532
XareltoRivaroxaban38$55,282
MounjaroTirzepatide47$50,785
JanuviaSitagliptin Phosphate38$47,783
FarxigaDapagliflozin Propanediol22$29,151
TradjentaLinagliptin29$18,730
MyrbetriqMirabegron22$18,529
LinzessLinaclotide12$18,252
VraylarCariprazine Hcl11$17,660
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$16,839
SymbicortBudesonide/Formoterol Fumarate33$15,288
OxycontinOxycodone Hcl21$14,993

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat$1,592$122,908140 claims
Lilly USA, LLCTrulicity, Mounjaro$2,289$122,318110 claims
Novo NordiskOzempic$651$91,90075 claims
PfizerEliquis$703$77,65177 claims
Johnson & JohnsonXarelto$280$55,28238 claims
AstraZenecaFarxiga, Symbicort$1,219$44,43955 claims
AbbVieLinzess, Vraylar, Synthroid$1,958$38,52644 claims
Astellas Pharma US IncMyrbetriq$556$18,52922 claims
GSKTrelegy Ellipta$1,516$16,83919 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$249$2,393276 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,067 internal medicine providers in Connecticut.

Other internal medicine in East Hartford

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →